AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc. (AIM) is expected to report earnings on November 6, 2026, before the market open. The consensus earnings estimate is a loss of $0.12 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -16.7% since its last earnings release on August 7, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.
Sector
Healthcare
Industry
Biotechnology